| Autor: |
Raffi F; CHU de Nantes, Nantes, France; †Grahame Hayton Unit, Royal London Hospital, London, United Kingdom; ‡Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; §Hotel Dieu University Hospital, Paris, France; ‖Southwest CARE Center, Santa Fe, NM; ¶Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA; #Hennepin County Medical Center, Minneapolis, MN; **University of Puerto Rico School of Medicine, Rio Piedras, PR; ††Jacobi Medical Center, Bronx, NY; ‡‡Southwest Infectious Disease Clinical Research, Dallas, TX; §§Pacific Oaks Medical Group, Beverly Hills, CA; and ‖‖Gilead Sciences, Foster City, CA., Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS |
| Abstrakt: |
In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%)]. Proteinuria, albuminuria, proximal renal tubular function, and bone mineral density improved after switching to TAF- from TDF-containing regimens. These longer-term data support FTC/TAF as a safe, well-tolerated, and durable nucleotide reverse transcriptase inhibitor backbone. |
